Date

9 July 2025

Location

Online via Webex, 1-2pm

About the event

Speakers from NHS England and NHS SPS provided an update about biosimilar and key generic medicines expected in 2025/26. There was a focus on aflibercept, golimumab, and denosumab and an opportunity to ask questions and share experience.

This webinar was intended for NHS procurement and clinical teams who will be implementing upcoming biosimilar and high value generic medicines. It was not recorded as some information is commercially confidential and subject to change.

Why it’s important

Implementation of biosimilar and key generic medicines requires collaborative working across the system. The use of biological medicines, including biosimilars, in clinical practice is expanding. Timely implementation and use of biosimilar and key generic medicines offers the NHS opportunities to deliver better value for certain conditions.

What was covered

Updated information to support planning and implementation for upcoming biosimilar and key generic medicines, specifically aflibercept, golimumab, and denosumab. 

There was an opportunity to ask questions of NHSE and NHS SPS colleagues

Speakers

Non-SPS speakers

Rebecca Burgoyne

Senior Medicines Policy Manager, Medicines Value & Access, NHS England

SPS speakers

• Danny Palmer
• Natalie Bryson
• Alison Ashman
• Daniel Hill
• Madeleine Foster

Future webinars

We plan to hold update webinars on the following dates:

• Thursday 11 September 2025
• Wednesday 10 December 2025

Save these dates in your diaries and look out for further information nearer the time.

Contact us

Please contact the admin team if you have any questions. 

Update history